Australia markets closed

Allakos Inc. (ALLK)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.1700+0.0400 (+1.88%)
At close: 04:00PM EDT
2.2100 +0.04 (+1.84%)
After hours: 07:46PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.1300
Open2.1400
Bid2.1700 x 1000
Ask2.4800 x 2200
Day's range2.0200 - 2.1700
52-week range2.0200 - 8.7300
Volume1,374,269
Avg. volume952,662
Market cap188.611M
Beta (5Y monthly)0.48
PE ratio (TTM)N/A
EPS (TTM)-1.4100
Earnings date06 Nov 2023 - 10 Nov 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.70
  • GlobeNewswire

    Allakos Appoints Neil Graham to its Board of Directors

    SAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Neil Graham, M.D. to the Allakos board of directors. Dr. Graham was the Chief Medical Officer of Tiziana Life Sciences Limited and currently serves on the board of directors of Aslan P

  • GlobeNewswire

    Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results

    SAN CARLOS, Calif., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2023. Recent Allakos Events Presented preclinical data at the European Academy of Allergy and Clinical Immunology (“EAACI”) Hybrid Congress 2023 highlighting lirentelimab and AK006

  • GlobeNewswire

    Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors

    SAN CARLOS, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Rand Sutherland, M.D. and Dolca Thomas, M.D. to the Allakos board of directors. Dr. Sutherland was the Chief Executive Officer of Seeker Biologics, a privately-held company, and curren